www.fdanews.com/articles/84592-amgen-prices-5-0-billion-convertible-senior-notes
AMGEN PRICES $5.0 BILLION CONVERTIBLE SENIOR NOTES
February 15, 2006
Biotechnology industry news provided by Financial News USA Amgen, the world's
largest biotechnology company, recently announced the pricing of $2.5 billion
principal amount of Convertible Senior Notes due 2011 and $2.5 billion principal
amount of Convertible Senior Notes due 2013, for an aggregate transaction size
of $5 billion.
Financial
News USA